AGED Diagnostics Is Chasing a Blood Test for 100 Million Livers

For the estimated 100 million Americans with fatty liver disease, the path to a definitive diagnosis often leads to an invasive and costly procedure: the liver biopsy. It is a clinical bottleneck that Rachel Zayas, a former MIT researcher turned founder, is betting a startup can solve with a vial of blood. Her company, AGED Diagnostics, is developing a noninvasive blood test designed to detect and stage metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis, aiming to move diagnosis earlier and out of the hospital [TEDCO, August 2025].

Founded in 2018 and based in the Rockville/Bethesda area, the biotech represents a classic, high-stakes diagnostic play. The ambition is not merely to add another test to the market, but to create a new standard for monitoring a silent epidemic, where early intervention can prevent progression to cirrhosis or liver failure. The company's recent $250,000 pre-seed investment from the TEDCO Pre-Seed Builder Fund is fueling its next critical step: a blinded clinical validation study across 15 to 25 sites [TEDCO, August 2025][F4, Unknown].

The Diagnostic Wedge

The core of AGED's approach is a proprietary analysis of biomarkers in blood plasma, rooted in genomic sequencing. The company conducts whole genome bisulfite sequencing on both liver tissue and plasma samples to identify epigenetic signatures that can discriminate between simple fat accumulation (steatosis) and the inflammatory liver cell damage of NASH, now more commonly termed MASH [Veeva CTV, retrieved 2026]. It also aims to stage the degree of accompanying fibrosis, the scarring that leads to organ failure.

This technical wedge targets the acknowledged shortcomings of today's standard of care. Liver biopsy, while the histological gold standard, is invasive, carries procedural risks, and suffers from sampling variability. Noninvasive alternatives like FibroScan or blood panels such as FIB-4 offer utility but can lack the precision needed for confident staging across the full spectrum of disease, particularly in early stages [AGED Diagnostics, retrieved 2026]. AGED's bet is that its multi-analyte, sequencing-based signature can deliver the accuracy of a biopsy without the needle.

Early Data and the Path to Clinic

Publicly disclosed data, while from early verification studies, forms the foundation of the company's claim. AGED reports completing a 300-patient verification study showing greater than 95% accuracy in differentiating simple steatosis from NASH and early from advanced fibrosis [F4, Unknown]. Earlier pilot work, cited in a Plug and Play Tech Center profile, suggested accuracy between 90% and 99% for distinguishing benign from advanced MASH [Plug and Play Tech Center, Unknown].

These figures, while promising, are prelude. The true test is the forthcoming multi-site validation study, a necessary precursor to seeking regulatory clearance from the FDA. A successful validation would provide the clinical evidence required to convince hepatologists, payers, and potentially pharmaceutical companies developing MASH therapies, who need reliable biomarkers for patient stratification and trial monitoring.

The Founder's Trajectory

The company is the vision of solo founder Rachel Zayas, a geneticist with a master's degree in biotechnology and business [F6S, Unknown]. Her path from MIT research in RNAi therapeutics to identifying a diagnostic gap in liver disease underscores a translational mindset [gamma.app, Unknown]. Zayas has also been an adjunct business instructor and was recognized on Pepperdine's Most Fundable Companies list, blending scientific depth with an early focus on commercial viability [River Jiang, LinkedIn, retrieved 2026].

While the core scientific team is described as including geneticists and hepatologists, the venture remains lean [MTEC, retrieved 2026]. The recent funding and participation in accelerators like the 2026 Global Innovation in Women’s Health program at Plug and Play are designed to build out that operational and commercial muscle [Plug and Play Tech Center, Unknown].

The Market and the Mandate

The commercial rationale is underpinned by a massive, growing patient population. Fatty liver disease is estimated to affect one in three Americans, with a global burden reaching approximately 2 billion people [AGED Diagnostics, retrieved 2026][47pitches, Unknown]. The subset with progressive MASH and fibrosis represents a target market AGED sizes at 25 million patients [47pitches, Unknown]. The global liver disease diagnostics market was valued at $32.2 billion in 2025 and is projected to grow steadily, indicating a receptive landscape for new tools [Yahoo Finance, retrieved 2026].

Success would mean securing a place in a diagnostic workflow that typically begins in a primary care or endocrinology setting, where a routine blood test showing elevated liver enzymes triggers a referral to a specialist. AGED's test would ideally be used by hepatologists and gastroenterologists to monitor disease progression and treatment response over time, reducing the cumulative need for biopsies.

The Risks in the Pipeline

For all its promise, AGED Diagnostics is navigating a path fraught with the standard perils of medtech. The company's next steps involve several key risks that will determine its trajectory.

• Clinical Validation. The reported >95% accuracy is from a verification study. The blinded, multi-site validation study is the necessary, and notoriously difficult, step to confirm those results in a broader, real-world population. Any significant drop in performance metrics would reset timelines and ambitions [F4, Unknown].
• Regulatory Hurdles. Bringing a novel diagnostic to market requires a successful FDA submission, either through the 510(k) or De Novo pathway. This process is costly, time-consuming, and demands robust clinical data. The company's disclosed $250,000 in funding is a start, but the capital required to complete a pivotal trial and regulatory review is typically an order of magnitude larger [TEDCO, August 2025].
• Commercial Adoption. Even with regulatory clearance, adoption is not guaranteed. The test must demonstrate clear clinical utility and cost-effectiveness to be adopted into guidelines and secure reimbursement from insurers. It must also compete for attention against entrenched imaging modalities and existing blood scores.

The company's most plausible answer to these challenges is a phased, evidence-driven approach. The current focus is squarely on executing the validation study to generate the data needed for the next, larger financing round. Partnering with established diagnostic laboratories or pharmaceutical companies could provide a pathway to market and de-risk commercial scaling.

The Patient at the End of the Test

The ultimate measure for AGED Diagnostics will be its impact on the lived experience of liver disease. For patients, the current standard of care creates a cycle of anxiety and inconvenience. A suspicious ultrasound or blood test leads to a referral, a wait for a specialist appointment, and then the prospect of a biopsy,a procedure that requires planning, carries a small risk of complications, and can be a barrier to repeated monitoring.

A reliable blood test could change that narrative. It could enable earlier detection during routine check-ups, allow for safe, frequent monitoring of disease progression, and help personalize treatment decisions. It represents a shift from reactive, invasive intervention to proactive, accessible management. The next twelve months, as AGED executes its validation study, will reveal whether its genomic signature in blood can truly begin to replace the scalpel in the liver clinic.

Sources

1. [TEDCO, August 2025] TEDCO Invests in AGED Diagnostics | https://www.tedcomd.com/news-events/press-releases/2025/tedco-invests-aged-diagnostics
2. [Plug and Play Tech Center, Unknown] AGED Diagnostics | https://www.plugandplaytechcenter.com/startup/ageddiagnostics-com
3. [F4, Unknown] AGED Diagnostics | Healthcare & Digital Health | F4 | https://f4.fund/startups/ageddiagnostics
4. [F6S, Unknown] Rachel Zayas | https://www.f6s.com/member/rachelzayas
5. [gamma.app, Unknown] Investment Opportunity | https://gamma.app/docs/Investment-Opportunity-1-jq4nakru4le8dy9
6. [Veeva CTV, retrieved 2026] AGED Diagnostics | https://www.veeva.com/ctv/company/aged-diagnostics/
7. [AGED Diagnostics, retrieved 2026] Home | AGED Diagnostics | https://www.ageddiagnostics.com/
8. [River Jiang, LinkedIn, retrieved 2026] River Jiang - University of California, San Francisco | LinkedIn | https://www.linkedin.com/in/riverjiang/
9. [MTEC, retrieved 2026] AGED Diagnostics | https://www.mtec-sc.org/portfolio/aged-diagnostics
10. [47pitches, Unknown] AGED Diagnostics | https://47pitches.com/startup/aged-diagnostics
11. [Yahoo Finance, retrieved 2026] Liver Disease Diagnostics Market | https://finance.yahoo.com/news/liver-disease-diagnostics-market-size-115800978.html